People: Dendreon Corp (DNDN.O)

DNDN.O on Nasdaq

1.03USD
24 Oct 2014
Price Change (% chg)

$-0.01 (-0.96%)
Prev Close
$1.04
Open
$1.04
Day's High
$1.05
Day's Low
$1.00
Volume
1,025,539
Avg. Vol
2,352,921
52-wk High
$3.52
52-wk Low
$0.89

Search Stocks

Summary

Name Age Since Current Position

Douglas Watson

69 2014 Chairman of the Board

W. Thomas Amick

71 2014 President, Chief Executive Officer, Director

Gregory Cox

48 2013 Interim Chief Financial Officer, Vice President, Treasurer

William Monteith

56 2013 Executive Vice President - Technical Operations

Lindsay Rocco

35 2012 Executive Vice President - Corporate Communications

Andrew Sandler

49 2014 Executive Vice President, Chief Medical Officer

William Jenkinson

43 2014 Chief Marketing Officer, Vice President

Robert Crotty

40 2014 Vice President, Interim General Counsel and Secretary

Karen Brophy

51 2014 Vice President, Head of Human Resources

Silvio Pacheco

48 2014 Vice President, Chief Customer Officer

David Urdal

64 2011 Director

Susan Bayh

54 2003 Independent Director

Bogdan Dziurzynski

65 2001 Independent Director

Dennis Fenton

62 2011 Independent Director

David Stump

64 2010 Independent Director

Biographies

Name Description

Douglas Watson

Mr. Douglas G. Watson is Chairman of the Board of Dendreon Corporation. Mr. Watson has served as a member of the Board of Directors since February 2000. Mr. Watson is Chief Executive Officer of Pittencrieff Glen Associates, a consulting firm that he founded in July 1999. From January 1997 to May 1999, Mr. Watson served as President and Chief Executive Officer of Novartis Corporation, the U.S. subsidiary of Novartis AG. From April 1996 to December 1996, Mr. Watson served as President and Chief Executive Officer of Ciba-Geigy Corporation, which merged into Novartis Corporation in December 1996. Mr. Watson’s career spanned 33 years with Novartis, having joined Geigy (UK) Ltd. in 1966. Mr. Watson also currently serves as Chairman of OraSure Technologies, Inc., a medical diagnostics company, and as a director of Delcath Systems, Inc., a specialty pharmaceutical and medical device company. Mr. Watson previously served on the Board of Directors of BioMimetic Therapeutics, Inc., a biotechnology company, from 1999 to March 2013, Genta Incorporated, a biopharmaceutical company, from 2002 to January 2011, Javelin Pharmaceuticals, Inc., a pharmaceutical company, from 2004 to 2010, and Engelhard Corporation, a surface and materials science company, from 1991 to 2006. Mr. Watson received an M.A. in Pure Mathematics from Churchill College, Cambridge University and holds an ACMA qualification as an Associate of the Chartered Institute of Management Accountants.

W. Thomas Amick

Mr. W. Thomas Amick is appointed as President, Chief Executive Officer, Director of Dendreon Corporation effective July 28, 2014. Mr. Amick brings to Dendreon significant experience within the pharmaceutical and life sciences industry. Most recently from 2010 to 2012, he served as chairman and chief executive officer of Discovery Labs, a specialty biotechnology company. Under his leadership, Discovery Labs was granted approval for Surfaxin, the first synthetic lung surfactant approved for use in premature infants. Prior to that, Mr. Amick enjoyed a highly successful 30-year career with Johnson & Johnson where, as vice president of the Ortho Biotech Oncology Franchise, he launched Procrit (epoetin alfa) and built J&J’s oncology franchise into a multi-billion dollar operation, making Procrit the most successful product in J&J history at the time. Mr. Amick also previously held positions as president of Ortho Biotech Europe, president of Janssen-Ortho Canada, and vice president of J&J Development Corporation (the venture capital division of J&J). Mr. Amick holds a B.S. degree in business administration from Elon University.

Gregory Cox

Mr. Gregory R. Cox has been appointed as Interim Chief Financial Officer, Vice President, Treasurer of Dendreon Corporation,since August 2013 and previously served as our Vice President of Finance and Accounting Operations from November 2005 to August 2013. Prior to joining Dendreon, Mr. Cox served as Vice President and Treasurer at Corixa Corporation from 1999 to 2005, responsible for developing corporate-wide business and financial strategies. He also served as Controller for Corixa from 1995 to 1999, where he led SEC compliance and reporting. Mr. Cox received his Bachelor of Arts degree in Accounting from Otterbein University and is a Certified Public Accountant.

William Monteith

Mr. William Monteith is Executive Vice President - Technical Operations of Dendreon Corporation, since January 2013. Previously he served as Vice President, Technical Operations Strategy from October 2012 to December 2012 and Vice President and General Manager of the Morris Plains, New Jersey manufacturing facility from May 2009 to October 2012. Prior to joining Dendreon, Mr. Monteith served as Vice President, Technical Operations at Sandoz Corporation, a division of Novartis, from June 2008 to May 2009. From July 2004 to June 2008, Mr. Monteith was Vice President, Operations at Shire Pharmaceuticals. Prior to July 2004, Mr. Monteith spent 22 years with Wyeth Pharmaceuticals in various roles with increasing responsibilities in the areas of manufacturing, technical support/validation, and quality operations. Throughout his 30-year career, Mr. Monteith has garnered experience in technical operations, quality assurance, and manufacturing operations. Mr. Monteith holds a Bachelor of Science degree in chemistry/pre-medical studies from Saint Lawrence University, Canton, New York.

Lindsay Rocco

Ms. Lindsay Rocco has been appointed as Executive Vice President - Corporate Communications of Dendreon Corp., effective November 14, 2012. Most recently, Ms. Rocco served as Senior Vice President and a member of the leadership team at Rx Mosaic Health from February 2010 to November 2012. Prior to that, Ms. Rocco served as a Director, Public Affairs at Roche-Genentech from June 2008 to January 2010. Throughout her career, Ms. Rocco has held senior-level positions with several healthcare public relations agencies within global holding companies, including the Omnicom Group and Publicis, and with MCS Healthcare Public Relations, an independent agency. She currently serves on the Board of Governors for the New York Chapter of the Arthritis Foundation. Ms. Rocco holds a Bachelor of Business Administration in Marketing from the Joseph A. Sellinger School of Business Administration and Management at Loyola University in Maryland.

Andrew Sandler

Dr. Andrew S. Sandler, M.D. has been appointed as Executive Vice President, Chief Medical Officer of the Company, effective February 1, 2014. He is site head of the Company’s operations in Seattle, Washington. Dr. Sandler also joins the Executive Committee.

William Jenkinson

Mr. William Jenkinson is a Chief Marketing Officer, Vice President of Dendreon Corp., since February 2014, and prior to that time he served as our Vice President, U.S. Marketing from May 2012 to February 2014. Prior to joining Dendreon, Mr. Jenkinson worked in both sales and marketing at Janssen Biotech, a Johnson & Johnson company, from March 2001 to May 2012. His last position at Janssen Biotech was Group Product Director, Marketing. Mr. Jenkinson earned his Bachelor of Arts from Georgetown University and his MBA from the College of William and Mary.

Robert Crotty

Mr. Robert L. Crotty has been appointed as Vice President, Interim General Counsel and Secretary of Dendreon Corporation. since February 2014 and previously served as Vice President, Assistant General Counsel and Assistant Secretary from April 2012 until February 2014. Previously, Mr. Crotty served as Senior Director, Senior Counsel and Assistant Secretary at NPS Pharmaceuticals, Inc., a biopharmaceutical company, from February 2009 until March 2012. From October 2006 until February 2009, Mr. Crotty held several positions at ImClone Systems Incorporated, a wholly-owned subsidiary of Eli Lilly and Company, and served as Senior Director, Senior Counsel and Assistant Secretary of ImClone prior to his departure. Prior to that time, Mr. Crotty worked at the law firms of Morgan Lewis & Bockius LLP from 2004 until October 2006, and Norton Rose Fulbright (f/k/a Fulbright & Jaworski) from 2001 until 2004. He earned his Bachelor of Arts from Princeton University and J.D. from University of Pennsylvania Law School.

Karen Brophy

Ms. Karen E. Brophy is a Vice President, Head of Human Resources of Dendreon Corp., since February 2014. She joined Dendreon in June 2012 as Director, Human Resources and served in that role until June 2013 when she became Senior Director, Human Resources, which she held from July 2013 to January 2014. Prior to joining Dendreon, Ms. Brophy consulted with Archimedes Pharma, a pharmaceutical company, from October 2011 to June 2012. Ms. Brophy served in a number of human resources positions at Celgene Corporation, a pharmaceutical company, from 2005 to 2011, most recently Director, Human Resources Operations from April 2009 to October 2011 and Director, Human Resources Staffing and Programs from March 2007 to March 2009. Earlier, she served in various human resources roles at Aventis Pharmaceuticals, Dun & Bradstreet and in the retail industry. Ms. Brophy earned her A.B. degree from Mount Holyoke College.

Silvio Pacheco

Mr. Silvio Pacheco is a Vice President, Chief Customer Officer of Dendreon Corp., since February 2014, and prior to that time served as our Vice President, Strategic Customer Group from February 2013 to January 2014. Prior to that role, he served as Senior Director, Head of Strategic Customer Group from May 2012 to February 2013. Before Dendreon, Mr. Pacheco served as Group Product Director at Janssen, a Johnson & Johnson company, from January 2011 to April 2012. Prior to assuming that role, Mr. Pacheco held multiple leadership positions in finance, marketing and sales at Janssen Biotech, including Group Product Director from January 2011 to May 2012 and Product Director from August 2008 to January 2011. Mr. Pacheco earned his Bachelor of Science from Rider University and his MBA from University of Phoenix.

David Urdal

Dr. David L. Urdal, Ph.D. is Director of Dendreon Corporation, since July 1995. Until his retirement in December 2011, he served as Executive Vice President and Chief Scientific Officer since December 2010, and previously served as Chief Scientific Officer and director since joining the Company in July 1995. He also served as Vice Chair of the Company’s Board of Directors from 1995 to June 2004, as Executive Vice President from January 1999 through December 2000, as the Company’s President from January 2001 to December 2003, and as Senior Vice President since June 2004. From 1982 until July 1995, Dr. Urdal held various positions with Immunex Corporation, a biotechnology company, including President of Immunex Manufacturing Corporation, Vice President and Director of Development, and head of the departments of biochemistry and membrane biochemistry. Dr. Urdal serves as a director of VLST, a biotechnology company and previously served as a director of ORE Pharmaceuticals, Inc., a pharmaceutical drug repositioning and development company, from 2007 until 2010. Dr. Urdal received a B.S. in zoology, a M.S. in Public Health and a Ph.D. in Biochemical Oncology from the University of Washington.

Susan Bayh

Ms. Susan B. Bayh is an Independent Director of Dendreon Corp. Prior to that, she served as a director of Corvas from June 2000 to July 2003. Ms. Bayh, retired since 2004, was a Distinguished Visiting Professor at the College of Business Administration at Butler University in Indianapolis, Indiana from 1994 to 2004. From 1994 to 2001, she was a Commissioner for the International Commission between the United States and Canada, overseeing compliance with environmental and water level treaties for the United States-Canada border. From 1989 to 1994, Ms. Bayh served as an attorney in the Pharmaceutical Division of Eli Lilly and Company. She currently serves on the Boards of Directors of Wellpoint, Inc., a health benefits company, Curis, Inc., a therapeutic drug development company, and Emmis Communications, a diversified media company, and previously served on the Board of Directors of Dyax Corp., a biotechnology company, from 2003 to March 2012 and MDRNA, Inc. (formerly Nastech Pharmaceutical Company Inc.), a biotechnology company, from 2006 to 2009. Ms. Bayh received a B.S. from the University of California, Berkeley and her J.D. from the University of Southern California Law School.

Bogdan Dziurzynski

Dr. Bogdan Dziurzynski is an Independent Director of Dendreon Corporation, since May 2001. Since 2001, Dr. Dziurzynski has been a consultant in strategic regulatory management to the biotechnology industry. Dr. Dziurzynski currently serves on the Board of Directors of Anthera Pharmaceuticals Inc. and previously served on the Board of Directors of the Biologics Consulting Group and Allostera Pharma Inc. Dr. Dziurzynski is a fellow and past Chairman of the Board of the Regulatory Affairs Professional Society. From 1994 to 2001, Dr. Dziurzynski was the Senior Vice President of Regulatory Affairs and Quality Assurance for MedImmune, Inc., a biotechnology company. From 1988 to 1994, Dr. Dziurzynski was Vice President of Regulatory Affairs and Quality Assurance for Immunex Corporation, a biotechnology company. Dr. Dziurzynski has a B.A. in Psychology from Rutgers University, an M.B.A. from Seattle University and a Doctorate in Public Administration from the University of Southern California.

Dennis Fenton

Dr. Dennis M. Fenton, Ph.D. has been appointed as an Independent Director of Dendreon Corporation, effective November 8, 2011. Dr. Fenton, who retired in 2008, previously held numerous positions from 1982 to 2008 at Amgen, Inc., a biotechnology company, including executive roles in process development, manufacturing, sales and marketing and research and development. From 2000 until 2008, Dr. Fenton was Executive Vice President responsible for worldwide operations, manufacturing, process development and quality. From 1995 until 2000, Dr. Fenton was Senior Vice President of Operations, and from 1992 until 1995, he was Senior Vice President of Sales, Marketing and Process Development. Prior to his time at Amgen, Inc., Dr. Fenton served as Senior Research Scientist at Pfizer, Inc., and previously was a research associate and graduate student at Rutgers University. Dr. Fenton currently serves as a member of the Board of Directors at Hopspira Inc., a publicly traded biopharmaceutical company, XenoPort, Inc., a publicly traded biopharmaceutical company, Kythera Biopharmaceuticals, Inc., a publicly traded biopharmaceutical company, Genelux Corporation, a biomedical company, and Napo Pharmaceuticals, Inc., a pharmaceutical company. He received his B.S. in Biology from Manhattan College and his Ph.D. in Microbiology from Rutgers University.

David Stump

Dr. David C. Stump, M.D. is an Independent Director of Dendreon Corporation, since June 2010. Dr. Stump was most recently at Human Genome Sciences, Inc. from November 1999 until December 2012. He served as Executive Vice President of Research and Development at Human Genome Sciences, Inc. from May 2007 to December 2012, Executive Vice President of Drug Development from December 2003 to May 2007, and Senior Vice President, Drug Development from November 1999 to December 2003. Prior to joining Human Genome Sciences, Inc., Dr. Stump held several positions at Genentech, Inc., including Vice President of Clinical Research, and was named a Genentech Fellow in 1996 for leadership of its cardiovascular drug development activities. Prior to Genentech, Dr. Stump served as Associate Professor of Medicine and Biochemistry at the University of Vermont. He is currently a member of the Board of Directors for Sunesis Pharmaceuticals, Inc., a pharmaceutical company, as well as of the Board of Trustees for Earlham College. Dr. Stump received his M.D. from Indiana University and his bachelor’s degree from Earlham College. Dr. Stump completed his residency and fellowship training in internal medicine, hematology, and oncology at the University of Iowa and is board certified in all three areas.
Search Stocks